Panel · Use case · Brand & Marketing

Over-the-Counter Switch Review.

LiveBenefit-Risk Panel

Can consumers self-select, use and self-monitor this product safely enough, and does access benefit outweigh the loss of prescriber oversight?

DecisionWhether a prescription-to-nonprescription switch is acceptable

FunctionsBrand, compliance, safety, medical information

ReaderConsumer health and safety leads

Not askedA switch application

DepthStandard, four seats

Over-the-Counter Switch Review is a ready-made use case for Brand & Marketing. It ships under the Benefit-Risk Panel template.

For brand and commercial leads. You get the effects table, each seat's conclusion, the weighing matrix, the uncertainties and the risk-minimisation measures. Claims are cited or marked as gaps.

Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.

The decision

Can consumers self-select, use and self-monitor this product safely enough, and does access benefit outweigh the loss of prescriber oversight?

Who weighs

A switch removes the prescriber. FDA expects evidence that consumers can understand the label, select themselves correctly and use the product safely, which is tested in label comprehension and self-selection studies.

Seat	What it weighs	What it works from
Global Brand Lead	The benefit of access and how consumers would find and use the product.	Consumer research.
Global Commercial Compliance Officer	Whether the label and marketing can support correct self-selection.^{1U.S. Food and Drug Administration. Label Comprehension Studies for Nonprescription Drug Products: guidance for industry. August 2010.}	FDA’s nonprescription label guidance.
Head of Pharmacovigilance	The risks without prescriber oversight and how misuse would be detected.	Safety data and post-market surveillance.
Medical Information Services Master	The questions consumers would ask and whether the label answers them.	Enquiry data.

What the assessment does

The label carries the safety. The weighing turns on whether a consumer can understand the label and decide correctly. The report reads the benefit against the evidence from comprehension and self-selection studies.^{1U.S. Food and Drug Administration. Label Comprehension Studies for Nonprescription Drug Products: guidance for industry. August 2010.}

Who is left out. Consumers who should not use the product must be able to identify themselves. The report lists groups at risk and the cue that would catch them.^{1U.S. Food and Drug Administration. Label Comprehension Studies for Nonprescription Drug Products: guidance for industry. August 2010.}

Monitoring after the switch. The report states how misuse would be detected and who would act on it.^{2U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategies (REMS).}

Recommended length

Standard

Four functions read the effects differently. Standard depth gives each a seat and shows the weighing matrix and the risk minimization table in about four pages.

You can pick another length on the form. The other two stay available.

Assumptions the assessment makes

The assessment states what it assumes about the evidence and the setting, and says what each gap limits. Examples for this decision:

Consumers in studies resemble real purchasers.
The condition can be self-diagnosed from the label.
Pharmacists will provide advice where the label calls for it.

Standards, guidance and sources

Frame

FDA, label comprehension studies for nonprescription drug products.^{1U.S. Food and Drug Administration. Label Comprehension Studies for Nonprescription Drug Products: guidance for industry. August 2010.}
FDA, REMS program, as a model of risk minimization options.^{2U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategies (REMS).}

The decision practice behind the memo itself is on the template page.

What gets flagged

Any benefit that assumes correct self-selection without study data, any at-risk group with no cue, and any monitoring plan with no owner.

What arrives

Decision and therapeutic context
Benefit-risk conclusion
Effects table
What each seat concludes
Weighing matrix by seat and criterion
Uncertainties and sensitivity
Risk minimisation and monitoring
What would change the balance

What it will not do

It does not replace a regulator or a benefit-risk committee. The conclusion is analyst judgment from AI specialists, and the decision stays with you.

It does not replace the studies a switch requires.

It does not replace a regulator or a benefit-risk committee. The conclusion is analyst judgment from AI specialists.

It does not compute a single benefit-risk score or invent patient preferences.

It does not add an effect that no source supports. Missing data are marked as gaps.

References

[1] U.S. Food and Drug Administration. Label Comprehension Studies for Nonprescription Drug Products: guidance for industry. August 2010. Title and date as known from FDA’s listing; not read.
[2] U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategies (REMS). Read on 9 October 2026 at its earlier address.

Links checked 9 October 2026

These are the sources the template drew on. None of their authors or issuers has reviewed it.

About the Panel service

Each panelist answers in their own voice, then the discussion is drawn together. You get the question and who was in the room, every position in full, what they agreed on, where they split, and what follows. Disagreements are written down rather than smoothed into a consensus nobody actually holds, because the split is usually the part you needed.

To edit a saved template, open New → Panel → From template, or the library rail on the service form.